Laboratoires Pierre Fabre
| Company type | Private limited company |
|---|---|
| Industry | Pharmaceutical |
| Founded | 1951 |
| Headquarters | Paris, France[1] |
Area served | Worldwide |
Key people |
|
Number of employees | 13,000 (2015) (Homepage) |
| Website | www |
Laboratoires Pierre Fabre is a French multinational pharmaceutical and cosmetics company. The company had a consolidated turnover of 1.978 billion euros in 2012 (including 54% international).[2] It is headquartered in the city of Castres, Midi-Pyrénées, France.[2]
Founded in 1962 by Pierre Fabre (1926-2013),[2] the company is present in over 130 countries. Laboratories Pierre Fabre had approximately 10,000 employees in 2012, 33% of whom are internationally based, while the remaining 6,700 employees were based in France.[2] The company's business activity is focused on research, development, manufacturing and marketing of cosmetics, prescription medicines and family health products. Pharmaceuticals and phytotherapy represent 47% of turnover, whereas cosmetics represent 53% (percentages of 2012 turnover).[citation needed]
Pierre Fabre is best known for its vinorelbine (Navelbine), an anticancer drug of the vinca alkaloid class.
Olivier Bohuon, now Chief Executive of Smith & Nephew, was Chief Executive from September 2010 to April 2011.
The Pierre Fabre Foundation
The Pierre Fabre Foundation was recognized as a public utility in 1999 and its mission is to help third-world countries to obtain quality drugs, ensure better quality control of drugs, use local therapeutic resources and train scientists for the inspection of drugs.
References
- ^ "Company Overview of Pierre Fabre S.A." Retrieved December 9, 2014.
- ^ a b c d "Pierre Fabre, founder of pharmaceutical giant, dies". Agence France Presse. France 24. 2013-07-20. Retrieved 2013-08-17.
External links
- Template:En icon Pierre Fabre laboratories - Official site
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |